SCHEMBL1829588

SCHEMBL1829588

CC(C)CCOCC(CO)OCCC(C)C

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.33
ALDH1A1 P00352 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.31
LPAR1 Q92633 4/20 0.31
LPAR3 Q9UBY5 4/20 0.31
LPAR2 Q9HBW0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28097159 0.92 TSHR (0.34) USP2ALDH1A1CNR1CNR2CA12
SCHEMBL10498218 0.87 ALDH1A1 (0.36) ALDH1A1TDP1CA12CA1CA2
SCHEMBL10762236 0.86 LMNA (0.42) USP2ALDH1A1CNR1CNR2
SCHEMBL1801332 0.86 LMNA (0.42) USP2ALDH1A1CNR1CNR2
SCHEMBL469524 0.86 USP2 (0.50) USP2ALDH1A1CNR1CNR2LPAR1
SCHEMBL25304331 0.86 LMNA (0.42) USP2ALDH1A1CNR1CNR2
SCHEMBL10761324 0.86 LMNA (0.42) USP2ALDH1A1CNR1CNR2
SCHEMBL10758278 0.86 LMNA (0.42) USP2ALDH1A1CNR1CNR2
SCHEMBL5707859 0.86 LMNA (0.42) USP2ALDH1A1CNR1CNR2
SCHEMBL25304326 0.86 LMNA (0.42) USP2ALDH1A1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116727928-A Soldering flux and preparation method thereof 乐清市荣兴金属材料有限公司 2023-09-12 CN claimed
CN-116727928-A Soldering flux and preparation method thereof 乐清市荣兴金属材料有限公司 2023-09-12 CN disclosed
CN-107082742-A Polyol ethers and the method for preparing them 陶氏环球技术有限责任公司 2017-08-22 CN disclosed
US-8829229-B2 Polyol ethers and process for making them DOW GLOBAL TECHNOLOGIES LLC (US) 2014-09-09 US disclosed
EP-2318346-B1 POLYOL ETHERS AND PROCESS FOR MAKING THEM DOW GLOBAL TECHNOLOGIES LLC (US) 2013-11-20 EP disclosed
WO-2011106194-A2 PROCESS FOR MAKING POLYOL ETHERS DOW GLOBAL TECHNOLOGIES LLC (US) 2011-09-01 WO disclosed
US-20110207969-A1 PROCESS FOR MAKING POLYOL ETHERS DOW GLOBAL TECHNOLOGIES LLC 2011-08-25 US disclosed
EP-2318346-A1 POLYOL ETHERS AND PROCESS FOR MAKING THEM Dow Global Technologies LLC (US) 2011-05-11 EP disclosed
WO-2010027663-A1 POLYOL ETHERS AND PROCESS FOR MAKING THEM DOW GLOBAL TECHNOLOGIES INC. (US) 2010-03-11 WO disclosed
US-20100048940-A1 reductive etherification of a polyol with an aldehyde or ketone using a hydrogenation catalyt; resulting compounds have use as solvents, surfactants, degreasers, wetting agents, emulsifying agents, lubricants, and intermediates for surfactants; polyols can be from renewable raw materials DOW GLOBAL TECHNOLOGIES LLC 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207969-A1 PROCESS FOR MAKING POLYOL ETHERS PUF60, PARG, PCBP1 USP2 989/4885ALDH1A1 3977/4885TDP1 4209/4885
US-20100048940-A1 reductive etherification of a polyol with an aldehyde or ketone using a hydrogenation catalyt; resulting compounds have use as solvents, surfactants, degreasers, wetting agents, emulsifying agents, lubricants, and intermediates for surfactants; polyols can be from renewable raw materials RNF114, USP14, USP13 USP2 70/4885ALDH1A1 692/4885TDP1 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.